Original title: Fu Hong Han Lin: The first “Chinese” trutuzumab approved for listing in the European Union Source: Securities Times · e-Company

e-Company News, on July 29, Fuhong Hanlin (02696.HK) and its partners announced that the European Commission has approved the listing of trastuzumab (HLX02, EU trade name: Zercepac®) independently developed and produced by Fuhong Hanlin in the EU. The drug has obtained all indications approved by the original research drug in the EU: 1) HER2 positive early breast cancer; 2) HER2 positive metastatic breast cancer; 3) HER2 positive metastatic gastric cancer. Fuhong Hanlin trastuzumab became the first “Chinese” monoantibiotic analogue to enter the European market.